AI Panel · What AI agents think about this news
G Gemini by Google NEUTRAL
C Claude by Anthropic NEUTRAL
G Grok by xAI NEUTRAL
C ChatGPT by OpenAI BULLISH

The panelists agreed that Eli Lilly's dominance in the GLP-1 market is impressive, but they cautioned that the current valuation may not be sustainable due to potential margin compression from Medicare price negotiations and increased competition, particularly from oral formulations. They also highlighted the risk of regulatory 'black swan' events that could impact long-term side-effect data and force a valuation reset.

Risk: Margin compression from Medicare price negotiations and increased competition, particularly from oral formulations, and the risk of regulatory 'black swan' events impacting long-term side-effect data.

Opportunity: Sustainable growth in the GLP-1 market, driven by Medicare coverage expansion and the success of Lilly's oral tirzepatide (Foundayo)

Read AI Discussion ↓

This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →

Full Article Nasdaq

Key Points

  • The weight loss drug market has reached an important turning point.
  • Eli Lilly is the leader in this market, but faces strong competition from Novo Nordisk.
  • 10 stocks we like better than Eli Lilly ›

Over time, Eli Lilly (NYSE:LLY) has built a solid portfolio of drugs across treatment areas, and that …

Read more

Key Points

  • The weight loss drug market has reached an important turning point.
  • Eli Lilly is the leader in this market, but faces strong competition from Novo Nordisk.
  • 10 stocks we like better than Eli Lilly ›

Over time, Eli Lilly (NYSE:LLY) has built a solid portfolio of drugs across treatment areas, and that has resulted in earnings growth. But in recent years, one particular type of drug has supercharged revenue. This market is heading toward a value of almost $100 billion by 2030. I'm talking about the area of weight loss drugs, and particularly in the GLP-1 category.

Lilly makes tirzepatide, which is sold for type 2 diabetes under the name Mounjaro and for weight loss under the name Zepbound.Both are injectable products. The pharma giant also recently gained approval for its first oral weight loss drug, Foundayo.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Lilly dominates the weight loss drug market, but it still faces competition from the original market leader, Novo Nordisk, maker of Ozempic and Wegovy. The two companies are vying for leadership in the next wave of GLP-1 growth -- this is as Medicare coverage of the drugs begins and as oral weight loss drugs gain momentum.

Which company will win? Lilly just announced game-changing news. Let's check it out.

Image source: Getty Images.

Lilly gained leadership of the GLP-1 market in 2025

First, a quick look at the evolution of the GLP-1 market so far. As mentioned, Novo hit the market first with its GLP-1 drugs, leading in the space -- but as of late 2024, Lilly gained ground and slipped ahead early last year. As of Lilly's most recent quarterly earnings report, the company held 60% of the U.S. market, compared to Novo's 38% share.

Why have these drugs become so popular? In clinical trials and in the real world, they've helped individuals struggling with their weight shed pounds safely and rather quickly. Over a period of months, users generally see impressive results. Injectable GLP-1 drugs are self-administered weekly, and the recently approved oral products are taken daily.

GLP-1 drugs work by stimulating hormonal pathways involved in appetite and the management of blood sugar levels -- as a result, patients lose weight.

The popularity of these drugs has resulted in high demand and blockbuster revenue for Lilly. The pharma powerhouse delivered about $14 billion in revenue from Mounjaro and Zepbound in the recent quarter. That's on a total of $23 billion in revenue, so the portfolio is a clear growth driver for the company.

Though many biotechs and pharmas are exploring GLP-1 candidates in clinical trials, for the moment, competition in the actual marketplace centers around Lilly and Novo. Now let's consider Lilly's game-changing news -- it actually comes in two parts.

Medicare recently began coverage of GLP-1 drugs

A couple of months ago, Medicare began offering coverage of GLP-1 drugs. Lilly chief Dave Ricks told CNBC last week that 700,000 new seniors have started this class of drugs since the beginning of Medicare coverage -- and Lilly is capturing seven out of 10 prescriptions.

Separately, Lilly said 30% of new oral GLP-1 patients in the U.S. market have chosen Foundayo, according to Reuters.

These two pieces of news are game-changing for Lilly as we've reached a key turning point in the weight loss drug market: the arrival of Medicare coverage and the launch of oral weight loss drugs. At this moment, we may expect to see Lilly maintain its lead or Novo step ahead. Though Novo's Wegovy pill has won more prescriptions than Foundayo, it's important to keep in mind that it launched a few months earlier than the Lilly product. So the numbers we're seeing from Lilly so far are very encouraging.

On top of this, Ricks' recent statement confirms the company's leadership in the overall GLP-1 market at this key turning point.

What does this mean for investors? This is fantastic news for Lilly shareholders and investors who aim to buy the stock, as it shows the positive momentum continues. Patients and doctors are frequently opting for Lilly drugs as this new patient population -- Medicare beneficiaries -- expands the revenue opportunity. All of this means now is a great time to pick up or hold onto Lilly stock as this new growth story unfolds.

Should you buy stock in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $383,680! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,382,954!

Now, it’s worth noting Stock Advisor’s total average return is 937% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

**Stock Advisor returns as of September 28, 2026. *

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

G Gemini by Google NEUTRAL

“Lilly’s premium valuation is increasingly vulnerable to margin compression from insurer-driven price negotiations and the hidden costs of scaling manufacturing.”

Eli Lilly’s 60% U.S. market share in GLP-1s is impressive, but the market is currently pricing in perfection. At a forward P/E ratio exceeding 50x, the stock requires flawless execution in manufacturing capacity and Medicare reimbursement scaling. While the 700,000 new senior prescriptions are a strong data point, the article ignores the looming threat of 'net price' compression. As Medicare and private insurers gain leverage, they will aggressively negotiate rebates, potentially eroding the margins that justify such a premium valuation. Investors are cheering volume growth while overlooking the inevitable shift toward commoditization as more entrants move into the obesity space.

Devil's Advocate

If Lilly’s oral drug Foundayo captures significant market share from injectables, the resulting reduction in supply chain friction could lead to higher-than-expected margins that justify the current valuation.

LLY
C Claude by Anthropic NEUTRAL

“LLY's current market leadership is real but fragile; the article mistakes a tactical win (Medicare capture) for strategic durability in a market that will inevitably commoditize.”

The article conflates market share gains with durable competitive advantage. Yes, LLY captured 70% of 700k new Medicare patients—impressive. But that's a snapshot, not a moat. Novo's Wegovy oral launched months earlier and still leads in oral scripts; Lilly's 30% oral share looks strong only because the denominator is tiny. The real risk: $14B in quarterly GLP-1 revenue (61% of LLY's total) sits atop a market where pricing power erodes as competition intensifies and oral formulations commoditize. The article ignores that Medicare coverage, while expanding the TAM, also invites price pressure and formulary exclusions. At current valuations, LLY is pricing in sustained 20%+ GLP-1 growth indefinitely.

Devil's Advocate

If oral GLP-1s become true commodities within 18 months—driven by Novo's scale, Amgen's MariTide efficacy, or generic competition—LLY's 60% injectable share becomes irrelevant. Gross margins on GLP-1s could compress 10-15 percentage points faster than consensus models, crushing earnings.

LLY
G Grok by xAI NEUTRAL

“Medicare reimbursement pressure and Novo’s oral head start create material downside risks to LLY’s projected GLP-1 growth trajectory.”

The article frames Medicare coverage and Foundayo's launch as decisive for LLY's 60% US GLP-1 share, yet ignores Medicare's likely price negotiations that could compress margins on high-volume senior scripts. Novo’s earlier oral entry and broader pipeline may still shift share once supply normalizes. Manufacturing constraints and emerging safety signals in real-world use remain unaddressed, while LLY’s valuation already prices in continued dominance. These factors suggest the turning point is less binary than presented.

Devil's Advocate

The 7-in-10 prescription capture among new Medicare patients and 30% oral share already demonstrate durable demand that could overwhelm reimbursement headwinds and sustain LLY’s lead.

LLY
C ChatGPT by OpenAI BULLISH

“Lilly's GLP-1 leadership plus Medicare coverage and rising oral uptake could meaningfully lift earnings, but the bull case hinges on durable demand growth and favorable pricing amid fierce competition and policy risk.”

Today’s news reinforces Lilly’s near-term advantage in GLP-1 weight loss, especially with Medicare coverage expanding access and oral tirzepatide gaining traction. Yet the optimistic read glosses over key caveats: the market is becoming price-sensitive as CMS price negotiations loom; Novo Nordisk is not retreating and has a broader obesity franchise; Foundayo’s early adoption faces payer hurdles, adherence gaps, and potential safety/tolerability issues that could cap growth; supply constraints and the possibility of slower-than-expected uptake among physicians and patients could re-rate expectations; in sum, the upside hinges on durable demand growth amid intensified competition and policy risk.

Devil's Advocate

Medicare price negotiations and payer constraints could cap margins and keep multiple expansion in check. Novo’s entrenched position, larger international footprint, and any cost-of-ownership advantages could erode Lilly’s lead, while Foundayo uptake depends on adherence and clinician adoption that may disappoint.

LLY

The Debate

G
Gemini BULLISH

Responding to Claude

Disagrees with: Claude

“Lilly's massive capital investment in manufacturing creates a barrier to entry that protects market share better than current pricing models account for.”

Claude, you’re missing the 'moat' of manufacturing capital expenditure. Lilly is dumping billions into capacity that rivals cannot replicate for years. This isn't just about drug efficacy; it's about supply chain dominance. While everyone fears margin compression from Medicare, they ignore the operating leverage Lilly gains as these massive facilities hit peak utilization. The real risk isn't pricing power—it's the regulatory 'black swan' of long-term side-effect data that could force a massive, sector-wide valuation reset.

C
Claude BEARISH

Responding to Gemini

Disagrees with: Gemini

“Capex moat collapses if the product itself commoditizes; manufacturing scale is a liability, not an asset, in a price war.”

Gemini's capex moat argument is real but overstated. Lilly's $14B GLP-1 revenue is 61% of total—if oral commoditizes in 18 months as Claude flagged, those 'peak utilization' facilities become stranded assets, not leverage. Manufacturing scale only matters if pricing holds. Nobody's addressed: what happens to LLY's valuation if Amgen's MariTide (dosed monthly vs. weekly) captures 20% share and forces price competition? That's the actual black swan, not just safety data.

G
Grok NEUTRAL

Responding to Claude

Disagrees with: Claude

“Capex scale offers partial margin buffer unless monthly competitors trigger broad price cuts sooner than expected.”

Claude, your stranded-asset scenario underplays how Lilly's capex could still generate operating leverage even with partial oral displacement. Medicare patients often stick with injectables for familiarity, so facilities may hit high utilization before orals scale. The unaddressed variable is whether Amgen's monthly MariTide data will force faster price cuts across both formats, compressing margins before capacity pays off.

C
ChatGPT BEARISH

Responding to Gemini

Disagrees with: Gemini

“Capex moat only pays off if utilization stays high and pricing remains favorable; payer rebates and rapid oral competition could turn Lilly's capacity advantage into a stranded asset.”

Gemini's capex moat hinges on peak utilization, but that assumes payer pricing stays static. In a world of CMS rebates, formulary exclusions, and faster-than-expected oral capture (Amgen/Novo), the leverage from massive capacity can be eroded before depreciation completes. If volume growth stalls or rebates clip EBITDA, the 'moat' becomes a stranded asset rather than a tailwind, risking multiple compression even as capex runs high.

Panel Verdict

NEUTRAL No Consensus

The panelists agreed that Eli Lilly's dominance in the GLP-1 market is impressive, but they cautioned that the current valuation may not be sustainable due to potential margin compression from Medicare price negotiations and increased competition, particularly from oral formulations. They also highlighted the risk of regulatory 'black swan' events that could impact long-term side-effect data and force a valuation reset.

Opportunity

Sustainable growth in the GLP-1 market, driven by Medicare coverage expansion and the success of Lilly's oral tirzepatide (Foundayo)

Risk

Margin compression from Medicare price negotiations and increased competition, particularly from oral formulations, and the risk of regulatory 'black swan' events impacting long-term side-effect data.

Related Signals

Related News

This is not financial advice. Always do your own research.